In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.

Abstract

BACKGROUND Mantle cell lymphoma (MCL) has the worst prognosis of all B-cell lymphomas and has poor response to conventional therapy. It is characterized by the presence of a chromosomal translocation t(11:14) (q13;q32) which results in deregulated cyclin D1 expression. Since defects in cell cycle regulation and apoptosis are primary events in MCL, small… (More)

Topics

Cite this paper

@article{Lacrima2005InVA, title={In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.}, author={Katia Lacrima and A. Valentini and Carla Lambertini and Mauro Taborelli and Andrea Rinaldi and Elisa Zucca and Carlo Vittorio Catapano and Fabio Cavalli and Athos Gianella-Borradori and David MacCallum and Francesco Bertoni}, journal={Annals of oncology : official journal of the European Society for Medical Oncology}, year={2005}, volume={16 7}, pages={1169-76} }